Jump to navigation (n)
Jump to content
Sitemap
About us
Back
Overview
Our strategy
Our board
Our executive team
Our history
Our investors
Our values
Innovation
Back
Overview
Our science
Platform and application
Patients & Families
Back
Overview
Treatments
Patient organisations
Clinical trials
About disease areas
Pipeline
News
Careers
Back
Overview
Vacancies
Contact
Menu
Search
News
Explore
NovalGen announces data presentation at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia
17.09.2021
NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
09.06.2021
NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma
20.05.2021
NovalGen receives CTA approval to start a Phase 1/2 first in human study to evaluate the safety, pharmacokinetics and efficacy of NVG-111 in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
07.04.2021
NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials
22.02.2021
NovalGen announces updates to its executive management team
19.02.2021
Novalgen licenses mAbsolve’s QumAb™ technology to improve the safety of therapeutic antibodies
06.10.2020
Media Coverage
Published in the March 2021 edition of MedNous, a publication of Evernow Publishing Ltd.
Read more
Home
About us
Back
About us
About us overview
Our strategy
Our board
Our executive team
Our history
Our investors
Our values
Innovation
Back
Innovation
Innovation overview
Our science
Platform and application
Patients & Families
Back
Patients & Families
Patients & Families overview
Treatments
Patient organisations
Clinical trials
About disease areas
Pipeline
News
Careers
Back
Careers
Careers overview
Vacancies
Contact
Search